A Novel Green Electrochemical Approach for the Determination of the Recently Approved Tyrosine Kinase Inhibitor Dacomitinib in Dosage Forms

The current study introduces the first voltammetric approach for the quantitation of the recently approved anticancer medication dacomitinib (DCN). The developed method is based on examining the electrode's voltammetric behavior with carbon paste. In this approach, both square wave and cyclic voltammetry were used. To achieve a satisfactory sensitivity, the measuring instrumental parameters were carefully studied using square-wave voltammetry. The limits of detection and quantitation were 6.7 × 10⁻⁷ and 2.0 × 10⁻⁶ M, respectively, indicating the method's high sensitivity. The anodic peak current increased linearly with DCN concentration over the range of 2.3 × 10⁻⁶–1.5 × 10⁻⁵ M upon adjusting the pH at 4 with Britton–Robinson buffer. The electrochemical method was fully validated as per the International Council of Harmonization (ICH) guidelines. The inter- and intra-assay precision relative standard deviation (%RSD) values were ≤1.809. This approach was applied to determine the drug in its pharmaceutical tablets (Vizimpro) with satisfactory %recoveries (98.8–100.9). The statistical results were favorably compared to those provided by a reported spectrofluorimetric method. The greenness and eco-friendliness of the designed approach were demonstrated using the Green Analytical Procedure Index (GAPI) and Analytical GREEnness (AGREE) tools, suggesting its usage as an environmentally friendly alternative for the routine assay of the investigated drug.